{"id":44816,"date":"2022-06-07T22:01:23","date_gmt":"2022-06-07T20:01:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/"},"modified":"2022-06-07T22:01:23","modified_gmt":"2022-06-07T20:01:23","slug":"orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/","title":{"rendered":"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers"},"content":{"rendered":"
\n

CHICAGO–(BUSINESS WIRE)–#accelerator<\/a>–A startup developing saliva-based diagnostics to screen for oral cancers and pre-cancers has won first place in the 26th Annual Edward L. Kaplan, \u201971, New Venture Challenge<\/a> (NVC), the signature venture competition for MBA students at the University of Chicago Booth School of Business.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nMore than $1.76 million in investment was awarded to the 11 finalist teams competing in NVC finals Thursday, the largest amount ever awarded in the history of the pioneering startup accelerator. The event was held in person for the first time since 2019.\n<\/p>\n

\n“Our finalist teams were spectacular and spectacularly diverse \u2014 from a test to detect cancer, to tiles for spacecraft, to a market for hydrogen, to wine and healthy food,” said Steven Kaplan<\/a>, the Neubauer Family Distinguished Service Professor of Entrepreneurship and Finance at the University of Chicago Booth School of Business and Kessenich E.P. Faculty Director of the Polsky Center for Entrepreneurship and Innovation, where he cofounded the NVC. “The strength of our teams was such that they generated a record amount of investment, surpassing last year\u2019s $1.73 million.”\n<\/p>\n

\nThe Rattan L. Khosa First-Place Prize, totaling $665,000 in investment, was awarded to OrisDX<\/a><\/b>, a venture that seeks to help alleviate the burden of cancer morbidity globally through greater access to non-invasive diagnostics and screening resulting in early detection of head and neck cancers. OrisDX, which is also a finalist in the George Shultz Innovation Fund<\/a> and was a participant in the Polsky Center’s I-Corps program<\/a>, is poised to launch a novel saliva-based molecular diagnostics test to detect pre-cancers and cancers of the oral cavity, based on science developed through a decade of foundational research by top physicians and scientists at the University of Chicago and Johns Hopkins University, including UChicago\u2019s Medicine\u2019s Nishant Agrawal<\/a>.\n<\/p>\n

\n“Our winning team exemplifies the growing collaborative powers of combining our Booth students with UChicago’s world-class researchers,” said Mark Tebbe<\/a>, an adjunct professor of entrepreneurship at Booth and an instructor of the NVC. “The innovativeness of this solution combined with its ability to potentially change medical procedures made it a clear winner in our very competitive NVC.”\n<\/p>\n

\n“We are so excited about today’s result, but even more excited about what this means to our future patients,” said Jake Stangl<\/a>, chief business officer at OrisDX and a current MBA student at Booth. “Our non-invasive diagnostic will make sure patients get the care they need early enough to ensure they live long and healthy lives. It’s been an honor competing against the other extremely talented teams, and being coached by some of the world’s greatest business leaders at the Polsky Center.”\n<\/p>\n

\nThe $25,000 Moonshot Prize<\/b>, awarded to a team whose unique technologies are catalyzing innovative solutions to global challenges, was split between the second- and third-place winners: BlackCurrant<\/b>, a hydrogen trading marketplace helping transportation companies access sustainable fuels, and Canopy Aerospace<\/a><\/b>, which is developing manufacturing processes for commercial thermal protection systems for the emerging space and hypersonic industries.\n<\/p>\n

\nThe $5,000 People’s Choice<\/b> award, a cash prize voted on by the audience, went to Earthi<\/b>, a grab-and-go fast-casual concept focused making healthy and delicious plant-based meals for flexitarians trying to reduce their meat consumption.\n<\/p>\n

\nSee here for the full list of the 2022 NVC winners and investment totals.<\/a><\/b><\/span>\n<\/p>\n

\nThe NVC was a pioneer of business school venture competitions when it held its first finals in 1997 with a $20,000 investment pool. It now has five tracks serving distinct UChicago audiences \u2014 including alumni, undergraduates, executive MBA students, and social impact entrepreneurs \u2014 and has graduated more than 370 startup companies still in operation today, including nationally known brands such as Grubhub, Braintree\/Venmo, Simple Mills, Tovala, and Foxtrot. NVC alumni have gone on to raise more than $1 billion in funding and achieve more than $8.5 billion in exits.\n<\/p>\n

\nThe competitive program spans the academic year, starting in the fall when students form teams and then apply to be in the program. Of 62 applications received this year, 30 teams were selected<\/a> to participate in the credit-bearing spring quarter course, where they took classes in entrepreneurship and received coaching to refine their pitches before finalists were selected to advance to the investment competition.\n<\/p>\n

\nThe finalist teams on Thursday presented their business plans to a judging panel made up of 22 investors, entrepreneurs, and industry leaders, many of them Booth alumni, who deliberated behind closed doors before announcing the record investment pool. All 11 finalists received investment.\n<\/p>\n

\nAbout the Polsky Center for Entrepreneurship and Innovation at the University of Chicago<\/b>\n<\/p>\n

\nThe Polsky Center for Entrepreneurship and Innovation applies world-class business expertise from the University of Chicago Booth School of Business to bring new ideas and breakthrough innovations to market. With a 60-person professional staff, the Polsky Center drives the creation of new ventures and commercial partnerships at the University of Chicago and beyond. As a global leader in entrepreneurship education, the Polsky Center is home of the Edward L. Kaplan, ’71, New Venture Challenge, one of the top accelerator programs in the nation. The Polsky Center provides training for aspiring entrepreneurs and those seeking a career in private equity, venture capital, and entrepreneurship through acquisition. Learn more at polsky.uchicago.edu<\/a> and follow updates on Twitter @polskycenter<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact: Alexia Elejalde-Ruiz, alexia.elejalde-ruiz@chicagobooth.edu<\/a><\/i>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CHICAGO–(BUSINESS WIRE)–#accelerator–A startup developing saliva-based diagnostics to screen for oral cancers and pre-cancers has won first place in the 26th Annual Edward L. Kaplan, \u201971, New Venture Challenge (NVC), the signature venture competition for MBA students at the University of Chicago Booth School of Business. More than $1.76 million in investment was awarded to the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-44816","format-standard","category-industry"],"yoast_head":"\nOrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHICAGO–(BUSINESS WIRE)–#accelerator–A startup developing saliva-based diagnostics to screen for oral cancers and pre-cancers has won first place in the 26th Annual Edward L. Kaplan, \u201971, New Venture Challenge (NVC), the signature venture competition for MBA students at the University of Chicago Booth School of Business. More than $1.76 million in investment was awarded to the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-07T20:01:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220607006248\/en\/1479529\/21\/OrisDx-win.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers\",\"datePublished\":\"2022-06-07T20:01:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/\"},\"wordCount\":880,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006248\\\/en\\\/1479529\\\/21\\\/OrisDx-win.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/\",\"name\":\"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006248\\\/en\\\/1479529\\\/21\\\/OrisDx-win.jpg\",\"datePublished\":\"2022-06-07T20:01:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006248\\\/en\\\/1479529\\\/21\\\/OrisDx-win.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220607006248\\\/en\\\/1479529\\\/21\\\/OrisDx-win.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/","og_locale":"en_US","og_type":"article","og_title":"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers - Pharma Trend","og_description":"CHICAGO–(BUSINESS WIRE)–#accelerator–A startup developing saliva-based diagnostics to screen for oral cancers and pre-cancers has won first place in the 26th Annual Edward L. Kaplan, \u201971, New Venture Challenge (NVC), the signature venture competition for MBA students at the University of Chicago Booth School of Business. More than $1.76 million in investment was awarded to the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-07T20:01:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220607006248\/en\/1479529\/21\/OrisDx-win.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers","datePublished":"2022-06-07T20:01:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/"},"wordCount":880,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607006248\/en\/1479529\/21\/OrisDx-win.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/","url":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/","name":"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220607006248\/en\/1479529\/21\/OrisDx-win.jpg","datePublished":"2022-06-07T20:01:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220607006248\/en\/1479529\/21\/OrisDx-win.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220607006248\/en\/1479529\/21\/OrisDx-win.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/orisdx-wins-665k-in-uchicagos-2022-new-venture-challenge-with-saliva-test-to-diagnose-oral-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"OrisDX Wins $665K in UChicago\u2019s 2022 New Venture Challenge with Saliva Test to Diagnose Oral Cancers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44816"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44816\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}